通过识别服务组成、结构和提供模式的有效成分探讨专科姑息治疗获益:一项系统综述与荟萃分析及荟萃回归
该系统综述与荟萃分析纳入39项国际随机对照试验,将结局转换为最小临床重要差异单位,发现专科姑息治疗在生活质量(13至36周标准化均数差0.40)和情绪健康方面均有获益,多学科、多组分和多场景模式效果更高,作者认为数据挑战了临终前才转诊的现行做法。
要点
- 专科姑息治疗在生活质量(13至36周标准化均数差0.40,95%CI 0.21至0.59)和情绪健康方面有统计学和临床显著获益。
- 多学科、多组分和多场景的服务模式效果更高,作者建议政策应推动基于需求的转诊,至少在死亡前3至6个月。
- 作者自述主要局限性为最小临床重要差异效应量可能因依赖非姑息治疗样本的推导而产生偏倚。
核心结论
- 使用新方法合并不同结局后发现,专科姑息治疗对生活质量和情绪健康有明确的中等总体效应量获益,且不取决于基础疾病;多学科、多组分和多场景模式最有效;作者认为数据严重挑战了临终前才转诊至专科姑息治疗的现行做法,政策和服务委托应推动基于需求的转诊,至少在死亡前3至6个月作为最佳照护标准。
研究设计与样本
- 系统综述与荟萃分析及荟萃回归,检索Cochrane、MEDLINE、CINAHL、ICTRP和clinicaltrials.gov(2000年1月1日至2023年12月28日),并补充手工检索会议摘要。
- 纳入随机对照试验,比较专科姑息治疗干预与常规照护,对象为成人生命限制性疾病患者,患者或代理报告结局作为主要或次要终点。
- 从42787条记录中纳入39项国际随机对照试验,其中38项来自高收入和中高收入国家。
- 使用Cochrane偏倚风险2工具评估偏倚/质量,使用GRADE工具评估证据确定性。
主要发现
- 生活质量(33项试验):从3个月随访起可见统计学和临床显著获益,13至36周标准化均数差(以最小临床重要差异单位计)效应量为0.40,95%CI 0.21至0.59,P<0.001,I²=60%。
- 生活质量13至36周:专科姑息治疗干预组13%的患者达到至少1个最小临床重要差异单位变化(RR=1.13,95%CI 1.06至1.20,P<0.001,I²=0%)。
- 情绪健康(22项试验):13至36周16%的患者达到至少1个最小临床重要差异单位变化(95%CI 1.08至1.24,P<0.001,I²=0%)。
- 生活质量需治疗人数从2周的69改善至3个月的15;情绪健康需治疗人数从2周的46改善至3个月的28。
- 多学科和多组分干预以及跨场景模式与更高效应量相关;使用稳健最小临床重要差异估计的敏感性分析显示生活质量有实质性获益、情绪健康有中等获益,且需治疗人数更低,即使随访更短。
临床怎么用
- 作者认为当前数据严重挑战了临终前才转诊至专科姑息治疗的现行做法。
- 作者建议政策和服务委托应推动基于需求的转诊,至少在死亡前3至6个月作为最佳照护标准。
局限性
- 最小临床重要差异效应量可能因依赖非姑息治疗样本的推导而产生偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Specialist palliative care (SPC) services address the needs of people with advanced illness. Meta-analyses to date have been challenged by heterogeneity in SPC service models and outcome measures and have failed to produce an overall effect. The best service models are unknown. We aimed to estimate the summary effect of SPC across settings on quality of life and emotional wellbeing and identify the optimum service delivery model. METHODS AND FINDINGS: We conducted a systematic review with meta-analysis and meta-regression. Databases (Cochrane, MEDLINE, CINAHL, ICTRP, clinicaltrials.gov) were searched (January 1, 2000; December 28, 2023), supplemented with further hand searches (i.e., conference abstracts). Two researchers independently screened identified studies. We included randomized controlled trials (RCTs) testing SPC intervention versus usual care in adults with life-limiting disease and including patient or proxy reported outcomes as primary or secondary endpoints. The meta-analysis used, to our knowledge, novel methodology to convert outcomes into minimally clinically important difference (MID) units and the number needed to treat (NNT). Bias/quality was assessed via the Cochrane Risk of Bias 2 tool and certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. Random-effects meta-analyses and meta-regressions were used to synthesize endpoints between 2 weeks and 12 months for effect on quality of life and emotional wellbeing expressed and combined in units of MID. From 42,787 records, 39 international RCTs (n = 38 from high- and middle-income countries) were included. For quality of life (33 trials) and emotional wellbeing (22 trials), statistically and clinically significant benefit was seen from 3 months' follow-up for quality of life, standardized mean difference (SMD in MID units) effect size of 0.40 at 13 to 36 weeks, 95% confidence interval (CI) [0.21, 0.59], p < 0.001, I2 = 60%). For quality of life at 13 to 36 weeks, 13% of the SPC intervention group experienced an effect of at least 1 MID unit change (relative risk (RR) = 1.13, 95% CI [1.06, 1.20], p < 0.001, I2 = 0%). For emotional wellbeing, 16% experienced an effect of at least 1 MID unit change at 13 to 36 weeks (95% CI [1.08, 1.24], p < 0.001, I2 = 0%). For quality of life, the NNT improved from 69 to 15; for emotional wellbeing from 46 to 28, from 2 weeks and 3 months, respectively. Higher effect sizes were associated with multidisciplinary and multicomponent interventions, across settings. Sensitivity analyses using robust MID estimates showed substantial (quality of life) and moderate (emotional wellbeing) benefits, and lower number-needed-to-treat, even with shorter follow-up. As the main limitation, MID effect sizes may be biased by relying on derivation in non-palliative care samples. CONCLUSIONS: Using, to our knowledge, novel methods to combine different outcomes, we found clear evidence of moderate overall effect size for both quality of life and emotional wellbeing benefits from SPC, regardless of underlying condition, with multidisciplinary, multicomponent, and multi-setting models being most effective. Our data seriously challenge the current practice of referral to SPC close to death. Policy and service commissioning should drive needs-based referral at least 3 to 6 months before death as the optimal standard of care.
引用
- Johnson MJ, Rutterford L, Sunny A, et al. Benefits of specialist palliative care by identifying active ingredients of service composition, structure, and delivery model: A systematic review with meta-analysis and meta-regression. PLoS Med. 2024. PMID: 39093900. doi:10.1371/journal.pmed.1004436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。